Zuben E Sauna

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi Understanding the contribution of synonymous mutations to human disease
    Zuben E Sauna
    Laboratory of Hemostasis, Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, 29 Lincoln Drive, Bethesda, Maryland 20892, USA
    Nat Rev Genet 12:683-91. 2011
  2. ncbi Characterization of conformation-sensitive antibodies to ADAMTS13, the von Willebrand cleavage protease
    Zuben E Sauna
    Laboratory of Hemostasis, Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
    PLoS ONE 4:e6506. 2009
  3. ncbi Detection of intracellular ADAMTS13, a secreted zinc-metalloprotease, via flow cytometry
    S Geetha
    Division of Hematology, Laboratory of Hemostasis, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Cytometry A 75:675-81. 2009
  4. ncbi Genomics and the mechanism of P-glycoprotein (ABCB1)
    Zuben E Sauna
    Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, DHHS, Building 37, 37 Convent Drive, Bethesda, MD 20892 4256, USA
    J Bioenerg Biomembr 39:481-7. 2007
  5. ncbi Inhibition of multidrug resistance-linked P-glycoprotein (ABCB1) function by 5'-fluorosulfonylbenzoyl 5'-adenosine: evidence for an ATP analogue that interacts with both drug-substrate-and nucleotide-binding sites
    Shinobu Ohnuma
    Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4256, USA
    Biochemistry 50:3724-35. 2011
  6. ncbi Aptamers as a sensitive tool to detect subtle modifications in therapeutic proteins
    Ran Zichel
    Laboratory of Hemostasis, Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
    PLoS ONE 7:e31948. 2012
  7. ncbi Mutations define cross-talk between the N-terminal nucleotide-binding domain and transmembrane helix-2 of the yeast multidrug transporter Pdr5: possible conservation of a signaling interface for coupling ATP hydrolysis to drug transport
    Zuben E Sauna
    Laboratory of Cell Biology, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892 4256, USA
    J Biol Chem 283:35010-22. 2008
  8. ncbi Catalytic cycle of ATP hydrolysis by P-glycoprotein: evidence for formation of the E.S reaction intermediate with ATP-gamma-S, a nonhydrolyzable analogue of ATP
    Zuben E Sauna
    Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4256, USA
    Biochemistry 46:13787-99. 2007
  9. ncbi Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer
    Zuben E Sauna
    Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, NIH and Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Cancer Res 67:9609-12. 2007
  10. ncbi Characterization of coding synonymous and non-synonymous variants in ADAMTS13 using ex vivo and in silico approaches
    Nathan C Edwards
    Laboratory of Hemostasis, Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
    PLoS ONE 7:e38864. 2012

Collaborators

  • Teresa M Przytycka
  • Anton A Komar
  • Noam Shomron
  • Anna Maria Calcagno
  • Peter Chiba
  • Scott L Friedman
  • Suresh V Ambudkar
  • Chava Kimchi-Sarfaty
  • In-Wha Kim
  • Nathan C Edwards
  • Ran Zichel
  • Shinobu Ohnuma
  • Courtni E Allen
  • Ryan Hunt
  • S Geetha
  • Krishnamachary Nandigama
  • Michael M Gottesman
  • In Wha Kim
  • Di Xia
  • Orsolya Polgar
  • William Plum
  • Jordan Newell
  • Idit Kosti
  • Wanida Chearwae
  • Robert Fathke
  • Vahan Grigoryan
  • Avital Perry
  • Basil Golding
  • Raheleh Salari
  • Chinyere Okunji
  • Zachary A Hing
  • Gouri Shankar Pandey
  • Yael Mandel-Gutfreund
  • Adam Blaisdell
  • Aaron Shapiro
  • David B Kopelman
  • Geetha S
  • Ettore Appella
  • Stewart R Durell
  • Lisa M Miller Jenkins
  • Eduardo Chufan
  • Kenji Soejima
  • Ryan C Hunt
  • Elizabeth Plum
  • Susan Garfield
  • Jung Mi Oh
  • Peter C FitzGerald
  • Xiang-Hong Peng
  • Michael Dean
  • Robert W Robey
  • Christopher Michejda
  • Kuniaki Morisaki
  • Nadya Tarasova
  • Susan E Bates

Detail Information

Publications21

  1. ncbi Understanding the contribution of synonymous mutations to human disease
    Zuben E Sauna
    Laboratory of Hemostasis, Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, 29 Lincoln Drive, Bethesda, Maryland 20892, USA
    Nat Rev Genet 12:683-91. 2011
    ..Here we review current understanding of the extent to which synonymous mutations influence disease, the various molecular mechanisms that underlie these effects and the implications for future research and biomedical applications...
  2. ncbi Characterization of conformation-sensitive antibodies to ADAMTS13, the von Willebrand cleavage protease
    Zuben E Sauna
    Laboratory of Hemostasis, Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
    PLoS ONE 4:e6506. 2009
    ..Conformation sensitive antibodies have been used to monitor protein conformation and to decipher the molecular mechanism of proteins as well as to distinguish functional and non-functional mutants...
  3. ncbi Detection of intracellular ADAMTS13, a secreted zinc-metalloprotease, via flow cytometry
    S Geetha
    Division of Hematology, Laboratory of Hemostasis, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Cytometry A 75:675-81. 2009
    ..Flow cytometry is a convenient, efficient, and cost-effective way to measure the expression levels of ADAMTS13...
  4. ncbi Genomics and the mechanism of P-glycoprotein (ABCB1)
    Zuben E Sauna
    Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, DHHS, Building 37, 37 Convent Drive, Bethesda, MD 20892 4256, USA
    J Bioenerg Biomembr 39:481-7. 2007
    ..Our results suggest that the power-stroke is provided only after formation of the pre-hydrolysis transition-like (E.S) state during ATP hydrolysis...
  5. ncbi Inhibition of multidrug resistance-linked P-glycoprotein (ABCB1) function by 5'-fluorosulfonylbenzoyl 5'-adenosine: evidence for an ATP analogue that interacts with both drug-substrate-and nucleotide-binding sites
    Shinobu Ohnuma
    Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4256, USA
    Biochemistry 50:3724-35. 2011
    ..Thus, FSBA is an ATP analogue that interacts with both the drug-binding and ATP-binding sites of P-gp, but fluorosulfonyl-mediated cross-linking is observed only at the NBDs...
  6. ncbi Aptamers as a sensitive tool to detect subtle modifications in therapeutic proteins
    Ran Zichel
    Laboratory of Hemostasis, Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
    PLoS ONE 7:e31948. 2012
    ..The technique can provide an early warning of structural changes during the manufacturing process that could have consequential outcomes downstream...
  7. ncbi Mutations define cross-talk between the N-terminal nucleotide-binding domain and transmembrane helix-2 of the yeast multidrug transporter Pdr5: possible conservation of a signaling interface for coupling ATP hydrolysis to drug transport
    Zuben E Sauna
    Laboratory of Cell Biology, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892 4256, USA
    J Biol Chem 283:35010-22. 2008
    ....
  8. ncbi Catalytic cycle of ATP hydrolysis by P-glycoprotein: evidence for formation of the E.S reaction intermediate with ATP-gamma-S, a nonhydrolyzable analogue of ATP
    Zuben E Sauna
    Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4256, USA
    Biochemistry 46:13787-99. 2007
    ....
  9. ncbi Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer
    Zuben E Sauna
    Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, NIH and Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Cancer Res 67:9609-12. 2007
    ..We discuss the importance of polymorphisms in drug metabolizing enzymes and transporters in anticancer therapy and suggest that synonymous polymorphisms may play a more significant role than is currently assumed...
  10. ncbi Characterization of coding synonymous and non-synonymous variants in ADAMTS13 using ex vivo and in silico approaches
    Nathan C Edwards
    Laboratory of Hemostasis, Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
    PLoS ONE 7:e38864. 2012
    ....
  11. ncbi Silent (synonymous) SNPs: should we care about them?
    Ryan Hunt
    Laboratory of Hemostasis, Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    Methods Mol Biol 578:23-39. 2009
    ..These changes can have a significant effect on the function of proteins, change cellular response to therapeutic targets, and often explain the different responses of individual patients to a certain medication...
  12. ncbi Plasma derivatives: new products and new approaches
    Zuben E Sauna
    Laboratory of Hemostasis, Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Biologicals 40:191-5. 2012
    ..Finally, novel technologies and potential products are emerging that utilize synthetic molecules in lieu of replacement proteins obviating the limitations associated with replacement therapies...
  13. ncbi About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work
    Zuben E Sauna
    Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, NIH, Building 37, Room 2120, 37 Convent Drive, Bethesda, MD 20892 4256, USA
    Mol Cancer Ther 6:13-23. 2007
    ..Based on the mutational and biochemical work on Pgp and structural studies with isolated NBDs, we review proposed schemes for the catalytic cycle of ATP hydrolysis and the transport pathway...
  14. ncbi A "silent" polymorphism in the MDR1 gene changes substrate specificity
    Chava Kimchi-Sarfaty
    Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Science 315:525-8. 2007
    ....
  15. ncbi The A-loop, a novel conserved aromatic acid subdomain upstream of the Walker A motif in ABC transporters, is critical for ATP binding
    Suresh V Ambudkar
    Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD 20892 4256, USA
    FEBS Lett 580:1049-55. 2006
    ....
  16. ncbi Multidrug resistance protein 4 (ABCC4)-mediated ATP hydrolysis: effect of transport substrates and characterization of the post-hydrolysis transition state
    Zuben E Sauna
    Laboratory of Cell Biology, Center for Cancer Research, NCI, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 4256, USA
    J Biol Chem 279:48855-64. 2004
    ....
  17. ncbi The conserved tyrosine residues 401 and 1044 in ATP sites of human P-glycoprotein are critical for ATP binding and hydrolysis: evidence for a conserved subdomain, the A-loop in the ATP-binding cassette
    In-Wha Kim
    Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Biochemistry 45:7605-16. 2006
    ..We named this subdomain the "A-loop" (aromatic residue interacting with the adenine ring of ATP)...
  18. ncbi Mutational analysis of ABCG2: role of the GXXXG motif
    Orsolya Polgar
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, USA
    Biochemistry 43:9448-56. 2004
    ..These studies support a hypothesis that the GXXXG motif promotes proper packing of the transmembrane segments in the functional ABCG2 homodimer, although it does not solely arbitrate dimerization...
  19. ncbi Biochemical basis of polyvalency as a strategy for enhancing the efficacy of P-glycoprotein (ABCB1) modulators: stipiamide homodimers separated with defined-length spacers reverse drug efflux with greater efficacy
    Zuben E Sauna
    Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4254, USA
    Biochemistry 43:2262-71. 2004
    ..These results suggest that polyvalency could be a useful strategy for the development of more potent Pgp modulators...
  20. ncbi The molecular basis of the action of disulfiram as a modulator of the multidrug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCC1)
    Zuben E Sauna
    Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4254, USA
    Mol Pharmacol 65:675-84. 2004
    ....
  21. ncbi Importance of the conserved Walker B glutamate residues, 556 and 1201, for the completion of the catalytic cycle of ATP hydrolysis by human P-glycoprotein (ABCB1)
    Zuben E Sauna
    Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4254, USA
    Biochemistry 41:13989-4000. 2002
    ....